Helix3

Executive Summary

Helix3 is a US-based contract research organization (CRO) that provides Good Laboratory Practice (GLP) compliant in vitro and in vivo laboratory services. Founded in 2017 and headquartered in San Francisco, the company differentiates itself by combining the innovative flexibility of academia with the rigorous quality and efficiency required for regulatory submissions. Leveraging a team with a collaborative history dating back to 1994, Helix3 offers customized research, method development, and regulatory study support to biotech and pharmaceutical clients. As a private CRO, it is well-positioned to benefit from the growing demand for outsourced drug development services, particularly in the preclinical stage. The company’s focus on GLP compliance ensures its services are critical for clients progressing toward regulatory filings, providing a steady revenue stream and opportunities for expansion into adjacent service areas.

Upcoming Catalysts (preview)

• Q3 2026Expansion of Service Offerings into New Modalities75% success
• Q4 2026Strategic Partnership with a Mid-Size Pharma Company70% success
• Q2 2026Accreditation for Additional Regulatory Standards80% success